Type 1 diabetes: Continuous glucose monitoring

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

The benefits of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes are sustained for at least 2 years, shows the extension of the ALERTT1 study.

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Most parents of children starting continuous glucose monitoring soon after their type 1 diabetes diagnosis find virtual initiation to be convenient and effective, shows a small study.

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.

The Dexcom G7 continuous glucose monitor is accurate and well tolerated for up to 10.5 days when worn on the arm or abdomen, a study of adults with diabetes suggests.

Individuals with type 1 diabetes continue to experience severe and level 2 hypoglycemia despite the use of continuous glucose monitoring systems, with the risk potentially influenced by personal beliefs, US research shows.

Use of continuous glucose monitoring within the first month of diagnosis is associated with an improvement in glycemic control among youth with type 1 diabetes, indicate findings from the 4T study.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Switching from intermittently scanned to real-time continuous glucose monitoring improves time in range by a clinically relevant percentage, show the findings of the 6-month ALERTT1 trial.

People with impaired hypoglycemia awareness become more proactive about treating low blood glucose when they start using continuous glucose monitoring, but do not adjust their insulin usage, show data from HypoDE.

People with type 1 diabetes who are “hyperglycemia aversive” reduce their hyperglycemia exposure at the cost of increased hypoglycemia and, potentially, reduced hypoglycemia awareness, research suggests.

The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.

The use of continuous glucose monitoring does not increase time in range in young children with type 1 diabetes, but may improve other glycemic indices, researchers report.

US researchers have identified racial disparities in the receipt of diabetes technologies among young adults with type 1 diabetes.

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.